Acelrx Pharmaceuticals (ACRX)

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary
ESG framework mentions
In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The Annual Meeting of the Company was held on June 17, 2021. Proxies for the Annual Meeting were solicited by the Board pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition. There were 119,102,999 shares of common stock entitled to vote at the Annual Meeting. A total of 67,447,154 shares were represented at the Annual Meeting in person or by proxy. The final votes on the proposals presented at the Annual Meeting were as follows:

Proposal No. 1

Adrian Adams, Richard Afable, M.D. and Mark G. Edwards were elected as Class I directors, by a plurality of the votes entitled to vote on the election of directors, to hold office until the 2024 Annual Meeting of Stockholders by the following vote:
NomineeForWithheldBroker Non-Votes
Adrian Adams16,857,41112,537,39538,052,348
Richard Afable, M.D.27,151,9622,242,84438,052,348
Mark G. Edwards27,033,1262,361,68038,052,348
In addition to the directors elected above, Vincent J. Angotti, Stephen J. Hoffman, M.D., Ph.D. and Pamela P. Palmer, M.D., Ph.D. will continue to serve as directors until the 2022 Annual Meeting of Stockholders, and Marina Bozilenko, Howard B. Rosen and Mark Wan will continue to serve as directors until the 2023 Annual Meeting of Stockholders, in each case until their successors are elected and qualified, or until their earlier death, resignation or removal.

Proposal No. 2

The selection by the Audit Committee of the Board of OUM & Co. LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021 was ratified by the following vote:

Proposal No. 3

The compensation paid to the Company’s named executive officers, as disclosed pursuant to